Status: Recruiting
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
The primary objective of this Pivotal study is to demonstrate the safety and effectiveness of the Pulse Biosciences nsPFA™ Cardiac Surgery System in treating atrial fibrillation during concomitant cardiac surgical procedures.
Participants needed: 135
Trial details
Age: 18-85Biological sex: AllType: InterventionalSponsor: Pulse Biosciences, Inc.Updated: Jan 12, 2026Locations: 2
Eligibility criteria
Subject must be between 18 and 85 years of age [+6]
Subject has an implantable electronic medical device. (i.e., pacemaker, implanta... [+34]